Logotype for Harrow Inc

Harrow (HROW) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Harrow Inc

Q3 2026 earnings summary

10 Nov, 2026

Executive summary

  • Q3 revenue reached a record $99.3M, up 39% YoY and 41% QoQ, led by branded products; FY 2026 revenue guidance was reaffirmed at $350M–$365M.

  • FY 2026 Adjusted EBITDA outlook was reset to more than $40M, including more than $33M in Q4, versus prior guidance of $80M–$100M.

Financial highlights

  • Q3 GAAP net income was $9.8M versus $1.0M a year earlier; nine-month net loss was $35.1M versus $11.8M.

  • Q3 Adjusted EBITDA was $21.2M versus $22.8M YoY and a $1.2M loss in Q2; nine-month Adjusted EBITDA was $7.3M.

  • Q3 operating income was $11.5M versus $14.7M YoY; gross margin was 75%, level with a year earlier and up from 71% in Q2.

  • Nine-month revenue was $214.2M versus $183.2M; nine-month operating cash flow was negative $27.4M versus positive $35.5M.

  • Cash and equivalents totaled $75.3M at September 30, 2026; notes payable, net, was $292.7M.

Outlook and guidance

  • FY 2026 revenue guidance remains $350M–$365M; it implies Q4 revenue of $135.8M–$150.8M, up 37%–52% sequentially, and Q4 Adjusted EBITDA above $33M.

  • Q4 is expected to be the strongest quarter to date, supported by VEVYE and TRIESENCE growth, IHEEZO seasonality, BYOOVIZ traction and TYRVAYA's first revenue contribution.

  • TYRVAYA is expected to contribute more than $30M in 2027 revenue; about $20M of new annual operating expenses are expected, primarily for commercial and operational costs.

  • OPUVIZ is planned for U.S. launch in 2027; G-MELT potential launch is anticipated in 2028.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Harrow